As the world’s largest healthcare company, Johnson & Johnson has a unique ability to apply its expertise and convening power to advance progress on some of the most difficult global health challenges. We strive to create long-term social value through delivering innovative medicines, vaccines, treatments and devices; improving access and affordability; supporting efforts to create stronger healthcare systems; and helping put a healthy mind, body and environment within reach of everyone, everywhere.
Our commitment to advancing global health equity incorporates our active efforts and collaborations to enhance access to medical treatment and healthcare for all people while breaking down historic racial and social barriers that hinder access to equitable healthcare solutions. Similarly, we contribute to increasing the resilience and capabilities of health systems so they can improve equitable access to healthcare for the long term. As a core priority embedded in our ESG ESG Environmental, social and governance strategy, global health equity is an imperative for Johnson & Johnson and for our stakeholders.
Facts About Health Inequities
We continue to expand our transformational medical innovation strategy to address additional diseases within our therapeutic areas, improve our early stage innovation capabilities and embrace advances in data science to drive effective, targeted and equitable solutions to diverse health needs. The COVID-19 pandemic demonstrated how rapidly the world can be disrupted by a major health crisis and how systemic inequities can adversely impact healthcare for all. However, COVID-19 also brought everyone at Johnson & Johnson together to harness our entire organization, knowledge, resources, and many longstanding and new partnerships to curb the pandemic through our COVID-19 vaccine and create a better, healthier future for all.